• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MetaVia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    5/21/25 8:30:17 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email
    0001638287false00016382872025-05-212025-05-21

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): May 21, 2025

    Graphic

    METAVIA INC.

    (Exact name of Registrant as Specified in Its Charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

    ​

    001-37809

    ​

    47-2389984

    (State or other jurisdiction

    of incorporation)

    ​

    (Commission

    File Number)

    ​

    (IRS Employer

    Identification No.)

    ​

    ​

    ​

    ​

    ​

    ​

    545 Concord Avenue, Suite 210

    Cambridge, Massachusetts

    ​

    ​

    02138

    (Address of principal executive offices)

    ​

    (Zip Code)

    ​

    (857) 702-9600

    (Registrant’s telephone number, including area code)

    ​

    Not applicable

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ​

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Title of each class

        

    Trading

    Symbol(s)

        

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    MTVA

     

    The Nasdaq Stock Market LLC

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    ​

    Item 8.01.Other Events.

    ​

    On May 21, 2025, MetaVia Inc. (the “Company”) posted an updated corporate presentation to its website at https://ir.metaviatx.com/events-presentations/presentations, which the Company may use from time to time in connection with presentations, investor communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    ​

    Forward-Looking Statements

    ​

    Exhibit 99.1 attached hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

    ​

    Item 9.01.Financial Statements and Exhibits.

    ​

    (d) Exhibits

    ​

    ​

    ​

    ​

    Exhibit
    Number

        

    Exhibit Description

    99.1

    ​

    Corporate Presentation dated May 21, 2025.

    104

    ​

    Cover Page Interactive Data File (embedded within Inline XBRL document).

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    ​

        

    METAVIA INC.

    ​

    ​

    ​

    ​

    ​

    ​

    Date: May 21, 2025

    ​

    By:

    /s/ Hyung Heon Kim

    ​

    ​

    ​

    Hyung Heon Kim

    ​

    ​

    ​

    President and Chief Executive Officer

    ​

    ​

    ​

    Get the next $MTVA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MTVA

    DatePrice TargetRatingAnalyst
    12/30/2024$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $MTVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Glickman Mark A was granted 28,147 shares, increasing direct ownership by 289% to 37,887 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      7/1/25 4:03:19 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Groves Jason L was granted 28,147 shares, increasing direct ownership by 160% to 45,699 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      7/1/25 4:02:49 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tursi James Patrick was granted 28,147 shares, increasing direct ownership by 310% to 37,219 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      7/1/25 4:02:24 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

      Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. Top-line data is expected in the fourth quarter of 2025. "T

      7/9/25 8:31:00 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

      CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of pre-clinical data on DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, demonstrating  additive hepatoprotective effects in combination with Efruxifermin, a fibroblast growth factor 21 (FGF21) analogue, in a metabolic dysfunction-associated steatohepatitis (MASH) mouse model. The data will be presented in a poster session, tomorrow, at the American Diabetes Association's 85th Scientific Sessions, taking place June 20-23, 2025, at the McCormick Place Convention Center in Chicago,

      6/21/25 9:00:00 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Life Sciences Investor Forum: Now Available for Online Viewing

      NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

      6/13/25 8:35:00 AM ET
      $ATNM
      $BPTH
      $COCH
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services

    $MTVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      6/4/25 4:01:12 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Dong-A St Co., Ltd bought $3,300,000 worth of shares (4,647,887 units at $0.71), increasing direct ownership by 87% to 9,995,679 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      5/20/25 4:16:39 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on MetaVia with a new price target

      H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

      12/30/24 7:25:48 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTVA
    SEC Filings

    See more
    • SEC Form EFFECT filed by MetaVia Inc.

      EFFECT - MetaVia Inc. (0001638287) (Filer)

      7/11/25 12:15:12 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by MetaVia Inc.

      424B3 - MetaVia Inc. (0001638287) (Filer)

      7/10/25 5:05:34 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MetaVia Inc. (0001638287) (Filer)

      7/9/25 9:00:29 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care